|Articles|February 23, 2011

Key Regulatory Issues for Dengue Vaccine Development

In this week's PLoS Medicine, Richard Mahoney and colleagues discuss two recent meetings convened by the Pediatric Dengue Vaccine Initiative and the Developing Countries' Vaccine Regulators Network on regulatory issues that need to be addressed before licensing dengue vaccines.

This work was supported by Bill & Melinda Gates Foundation grant# 23197. The

Reference: Mahoney R, Chocarro L, Southern J, Francis DP, Vose J, et al. (2011) Dengue Vaccines Regulatory Pathways: A Report on Two Meetings with Regulators of Developing Countries. PLoS Med 8(2): e1000418.doi:10.1371/journal.pmed.1000418


Related to this article

Infection preventionists in full PPE with children in DRC.  (Image credit: author with AI)
Nearly 4 months into the DRC's Bundibugyo virus disease outbreak, some indicators suggest transmission may be slowing. But shifting hotspots, treatment-center capacity problems, community deaths, and incomplete surveillance data show why national case totals alone cannot determine whether containment has been achieved.